Sun Pharmaceutical Industries is currently trading at Rs 792.75, up by 1.70 points or 0.21% from its previous closing of Rs 791.05 on the BSE.
The scrip opened at Rs. 791.50 and has touched a high and low of Rs. 798.30 and Rs. 790.75 respectively. So far 31242 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.
Last one week high and low of the scrip stood at Rs. 809.30 and Rs. 732.00 respectively. The current market cap of the company is Rs. 190607.95 crore.
The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 35.62% and 9.68% respectively.
Sun Pharmaceutical Industries’ wholly-owned subsidiary - Sun Pharma Laboratories has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000, ‘AAA / Stable Outlook’ Rated by ICRA, Unsecured Redeemable Non-Convertible Debentures of a face value of Rs 10,00,000 each to be listed on BSE under two series with Series 1 debentures comprising of 5,000 debentures amounting to Rs 500 crore with a tenor of 24 months, and Series 2 debentures comprising of 5,000 debentures amounting to Rs 500 crore with a tenor of 39 months.
Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: